We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 3.57% | 14.50 | 14.00 | 15.00 | 15.00 | 14.00 | 14.00 | 1,310,616 | 10:04:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -1.74 | 37.78M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/3/2024 08:15 | Twogood2die on LSEBones699Paul Planet Earth Same person. CLOWN | zeus19 | |
08/3/2024 08:14 | Yup do your own research..£130m cash burnt through and down to just 6 months cash left in the kitty...absolutely zero commercial deals in the pipeline and the cash runway into Q2 2025 looks absurdly unattainable meaning an inevitable cash raise and probably sub 12p unless Newland can pull the wool over investors eyes! | bones699 | |
08/3/2024 08:08 | There's only one thing sad round here...and it ends in 699....should have done it ages ago....filtered... | sawney | |
08/3/2024 08:01 | Feeling very positive this morning! Everything pointing to good preparation for commercialization phase now with new specialist recruitment underway. Company has already stated cash runway well into 2025 News on further data likely Not sure why some people have something against this company?? Do you own research | spa362 | |
08/3/2024 07:38 | Oh dear how sad from the LSE BB. TwoGood2Die Cash Running Out! Today 07:35 "June 2023 they had £20m cash remaining by December they had no doubt burnt through £9m and despite the US lab closure are probably still burning through well over £1m a month meaning only £7m cash remaining enough to last just 6 months till Q3 this year....yet still no signs of that elusive £6m Newland promised!....maybe AGL needs to consider other alternative 'strategic initiatives' to a cash raise as referenced at January's Investor Meet, whatever that was supposed to mean, no details provided by Newland, that figures!" | bones699 | |
07/3/2024 20:32 | What a daft analogy...keep falling off your chair.You sit on it long enough now as you got sacked...rumour has it.Dr James M ReubenWe look forward to the further development of CTC based assays that may bring enormous benefits to patients with MBC as well as other cancers in the future."It's the first mover advantage that is so valuable here | muffster | |
07/3/2024 17:03 | Unfortunately that's the reality here Newland sold an empty dream to investors. If you recall at the Investor Meet in London back in January when asked about FDA approval...Newland replied by saying that Parsortix could be used for testing other cancers than breast cancer so long as the laboratory concerned seeks accreditation from the FDA to do so. ...at which point I nearly fell out of my chair.. ..Its bit like a car salesman saying to a would be buyer the new car can be used for going up to speeds of 10 mph in first and second gears only but if you want it go much faster you need to apply to the NCAP 'New Car Assessment Program' to ensure the vehicle meets all the stringent safety points and regulations! Hence why Parsortix has had zero commercial deals signed to date. | bones699 | |
07/3/2024 15:23 | FFS,they better start generating some significant revenue streams! Solaris must be properly pi..ed off! Abbot presumably nowhere to be seen,along with Philips and the other machinery Makers. Are we going to become solely a consumables supplier? Somebody please take us out! | fhmktg | |
07/3/2024 13:14 | Prostate and Ovarian kicked into long grass and that delay as well as with KRAS and EGFR obscured by big fanfare and new marquee project on BiDetect The delay either deliberate refocus or I think more likely they suffered delays with third party equipment and have now had to bring in house. The samples for these two LDTs were in storage last we heard to be run later in 2024 | bagpuss67 | |
07/3/2024 12:53 | Yup let's start recruiting now when that should have been done last year..It takes a very long time to establish sales networks and contacts and time is marching on and no commercial deals have been established while cash is running out! The other way to look at things why aren't the two largest laboratory chains in the USA Quest Diagnostics and LabCorp not interested? | bones699 | |
07/3/2024 10:59 | Wouldn't that depend on whether the sales people actually prove to be any good? I hope we can take some comfort from the fact they appear to believe they actually have something to sell. | arthur_lame_stocks | |
07/3/2024 10:55 | Re the two job offers, it sounds to me as though they aren’t generating enough interest from anywhere,so now they want a telephone sales person to generate leads for a senior sales person to go and try and sell the products, doesn’t bode well. | bobbie121 | |
07/3/2024 07:12 | Another positive indicator that to date AGL haven't generated any commercial deals and are very unlikely to do so in future. Q2 about to start and absolutely no signs of Newlands fabbled £6m additional revenues.. "Hello Mr Large USA Lab Chain, I have got a new testing machine called Parsortix its great at testing for just one cancer that's like 4% of all cancers...but don't you worry you can test it for all known cancers as long as you are accredited"...Newlan Two seconds later the door is slammed firmly in his face! | bones699 | |
06/3/2024 14:55 | I also note NEW positions at AGL (posted today) - another positive indicator:-SENIOR SALES MANAGER - BIOPHARMA SERVICES: The role of the Senior Biopharma Service Sales Manager is to drive revenue growth for ANGLE's biopharma services, assay development programs, and strategic alignments within the life science industry. This is done by proactively approaching potential customers within the life science industry (pharma, academic centres, esoteric laboratories, etc.) where ANGLE's Parsortix and liquid biopsy services can be of great value in support of their oncology drug development and companion diagnostic test development process. This role will work directly with the Chief Commercial Officer, R&D, clinical team, product sales, product managers and marketing.-INSIDE SALES REP: Works in tandem our sales team to provide customers with ANGLE liquid biopsy solutions. Main responsibilities will be to generate high quality sales leads including pharmaceutical, biotechnology and esoteric CLIA laboratories, that fall directly within ANGLE's target market segment.?The job holder will help drive global sales and is accountable to meet established sales targets. This position interfaces with multiple departments across the organisation, to represent customer and sales force interests.-Https://a | 5oletrader | |
06/3/2024 12:26 | Nice to see a bit of buying News cant be far off | rb1947 | |
06/3/2024 10:25 | Jelenko - it doesn't think period. It's not about content and more about volume. That's why it's easy to ignore. | boris cobaka | |
06/3/2024 09:23 | Bones Exactly so - 'FDA are there for a reason to prevent misdiagnosis and miss use (sic) of the wrong drugs' etc. etc. You have simply highlighted what a huge achievement it is for this small UK company to secure the world's first and only FDA approval for CTC capture for subsequent analysis. It validates the system and gives Angle a huge competitive advantage in a rapidly emerging market. | bermudashorts | |
06/3/2024 09:09 | FDA not required if the company using it does so in a lab that has certain accreditation and you can be sure that the major pharma's have this so its no longer an issue. Having ben awarded approval for one cancer situation gives validation to the Parsotix system full stop.Too much typing not enough thinking..!!! | jelenko | |
06/3/2024 08:39 | FDA approval is there for a reason to prevent misdiagnosis and miss use of the wrong drugs and treatments which could be fatal..This is an investment case without full FDA approval Parsortix has no future, period! | bones699 | |
06/3/2024 08:35 | 'Shame aint it that Parsortix is only FDA approved for testing 1 of 24 major cancer groups!..🤒 bones699...If your wife or daughter was dying of cancer, wouldn't you be interested in knowing which one it is or is not? | htrocka2 | |
06/3/2024 08:08 | Shame aint it that Parsortix is only FDA approved for testing 1 of 24 major cancer groups!..🤒 | bones699 | |
06/3/2024 08:06 | Time for a top-up methinks. Ready for the next burst to 20p. Amazing value with full patents and clearance in the US! Big Pharma looking..... | philjeans | |
06/3/2024 07:49 | Good spot Bermudashorts. Meanwhile the undernoted article underlines (what we already know) re the importance of Angles Parsortix technology & particularly in light of the recent molecular results. H ttps://www.bristolpo Ps.Delete space after H for link | gooosed |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions